ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
化学式:
(CH3)2CHCH=CH(CH2)4CONHCH2C6H3-4-(OH)-3-(OCH3)
CAS番号:
分子量:
305.41
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
206-969-8
Beilstein/REAXYS Number:
2816484
MDL number:
grade
pharmaceutical primary standard
agency
EP Reference Standard
API family
capsaicin
manufacturer/tradename
EDQM
mp
62-65 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O
InChI
1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+
InChI key
YKPUWZUDDOIDPM-SOFGYWHQSA-N
Gene Information
human ... TRPV1(7442)
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Application
Capsaicin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
プロトタイプバニロイド受容体アゴニスト。神経毒；無髄の C 線維をもたらす感覚ニューロンを活性化し、その多くにはサブスタンス P が含まれています。局所塗布をすると、感覚神経終末が感度が低下し、逆説的な抗侵害受容効果が得られます。全身投与を行うと、特に新生仔動物においてカプサイシン感受性細胞に対して神経毒性を示す可能性があります。トウガラシの活性成分。
プロトタイプバニロイド受容体アゴニスト；神経毒。トウガラシの活性成分。
Packaging
この製品は発行元の薬局方による供給としてお届けします。現在の単位量については、EDQM reference substance catalogueをご覧ください。
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under カプサイシン
signalword
Danger
Hazard Classifications
Acute Tox. 2 Oral - Eye Dam. 1 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
保管分類
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
235.4 °F - closed cup
flash_point_c
113 °C - closed cup
Helen Sumner et al.
American journal of respiratory and critical care medicine, 187(9), 943-949 (2013-03-09)
Cough is one of the principal symptoms of chronic obstructive pulmonary disease (COPD) but the potential drivers of cough are likely to be multifactorial and poorly understood. To quantify cough frequency in an unselected group of subjects with COPD and
Emma C Y Hilton et al.
The Journal of allergy and clinical immunology, 132(4), 847-855 (2013-06-20)
Inhaled capsaicin elicits cough reproducibly in human subjects and is widely used in the study of cough and antitussive therapies. However, the traditional end points C2 and C5 (the concentrations of capsaicin inducing at least 2 or 5 coughs, respectively)
Sheena Derry et al.
The Cochrane database of systematic reviews, 2(2), CD007393-CD007393 (2013-03-02)
Topical creams with capsaicin are used to treat peripheral neuropathic pain. Following application to the skin capsaicin causes enhanced sensitivity, followed by a period with reduced sensitivity and, after repeated applications, persistent desensitisation. High-concentration (8%) capsaicin patches were developed to